Bristol-Myers Squibb, the $20 billion (sales) pharmaceutical giant, has put itself up for sale, according to a news report from Reuters. Itself a product of the 1989 merger of Bristol-Myers and Squibb Corporation, the company is said to be examining a number of options, including a possible combination with GlaxoSmithKline.

Click here to read the Reuters report.